Y-mAbs Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $123.32 Mil.
During the past 12 months, Y-mAbs Therapeutics's average Total Assets Growth Rate was 6.10% per year.
During the past 3 years, the average Total Assets Growth Rate was 41.40% per year.
During the past 5 years, the average Total Assets Growth Rate was 63.00% per year.
During the past 8 years, Y-mAbs Therapeutics's highest 3-Year average Total Assets Growth Rate was 188.10%. The lowest was 41.40%. And the median was 97.00%.
The historical data trend for Y-mAbs Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Y-mAbs Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Y-mAbs Therapeutics (NAS:YMAB) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Y-mAbs Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Y-mAbs Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of Y-mAbs Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Y-mAbs Therapeutics (Y-mAbs Therapeutics) Business Description
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas. The vast majority of the Company's product sales are generated in the United States with additional sales outside the United States in China and Israel through sublicenses and distribution agreements.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
YMAB has been successfully added to your 